StockNews.com assumed coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Free Report) in a research note released on Friday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pieris Pharmaceuticals Stock Down 15.7 %
Shares of NASDAQ:PIRS opened at $13.60 on Friday. Pieris Pharmaceuticals has a 52-week low of $6.20 and a 52-week high of $22.32. The stock has a market cap of $17.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.61. The business has a 50-day moving average price of $15.31 and a 200-day moving average price of $14.97.
Hedge Funds Weigh In On Pieris Pharmaceuticals
An institutional investor recently bought a new position in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. purchased a new stake in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned approximately 1.21% of Pieris Pharmaceuticals at the end of the most recent quarter. 40.11% of the stock is currently owned by institutional investors.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.
Further Reading
- Five stocks we like better than Pieris Pharmaceuticals
- What is a SEC Filing?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What Makes a Stock a Good Dividend Stock?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Using the MarketBeat Dividend Tax Calculator
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
